Guggenheim raised the firm’s price target on Centessa (CNTA) to $28 from $24 and keeps a Buy rating on the shares after the company “pre-empted the Street with a compelling” Single Ascending Dose/Multiple Ascending Dose update from ORX750. These data confirm the medicine’s best-in-class profile while addressing key unanswered questions on tolerability, dose response, and next steps, the analyst contends.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA: